Obsessive Compulsive Disorder

Epidemiology

Comorbidity

OCD and Tic Disorder

OCD and Depression

OCD and Other Anxiety Disorders

OCD and Phobia

OCD and OCPD

OCD and Schizophrenia

Course and Prognosis

Etiology

Specific Clinical Response

Serotonin Antagonists

Pharmacological Challenges

Dopamine

Immune Factors

Brain Imaging Studies

Genetics

Other Biological Data

Behavioral Factors

Psychosocial Factors

Treatment of OCD

Efficacy of Serotonergic vs Adrenergic Antidepressants

Long Term Treatment of OCD

Drug Dosage

Psychological Approaches

Treatment Resistant OCD

Switching Medications

Augmentation

Risperidone

Pindolol

Other Options

Intravenous Clomipramine

Monoamine Oxidase Inhibitors

Last-line Therapies

Overcoming Anxiety (Home) > Obsessive Compulsive Disorder > Switching Medications

Switching Medications

If the patient could not tolerate adequate doses of SSRIs or has not responded to SSRI administered in the upper range of the relevant dose, a trial of CMI is recommended (and vice versa). CMI should be given after an adequate work-up that includes an ECG and ruling out ophthamological problems (i.e. closed angle glaucoma). Although no fixed dose studies were carried out, it seems that high doses of CMI are needed in order to attain responses in OCD patients. The titration to these doses should last for 1–3 weeks. If possible, therapeutic drug monitoring should be performed in order to ascertain blood levels (200–500 ng/ml) for the parent drug plus the desmethyl derivative and to avoid side-effects that result from very high (or even toxic) blood levels.

If tolerated, a dose of 200–300 mg/day is considered efficacious in OCD, and this dose would be administered for 10 weeks before determining a lack of response. Caution is necessary if CMI is administered immediately after fluoxetine; in this case, lower initial doses of CMI should be the rule, due to fluoxetine’s long half-life and the fact that it inhibits cytochrome P450 enzymes (thus increasing the availability of CMI). Switching from SSRIs, with shorter half-lives and less inhibition of cytochrome P450 enzymes (such as fluvoxamine and sertraline) to CMI is less problematic. However, the common procedure of slow titration is recommended

	More Articles
1. Areas of Controversy Debate Areas of Controversy and Debate Since the introduction of the DSM-III, the nosological position of PD has been controversial. Two main positions [...]
2. Manic Depression: Causes, Symptoms and Treatment Manic Depression Truly Painful: Causes, Symptoms and Treatment You are a wonderful and intelligent person, and you feel that you [...]
3. Early Life Events Early Life Events It has been suggested that there may be a link between the experience of traumatic life events during childhood and adolescence and the development [...]
4. Helpful Information About Depression Needed Helpful Information you Really Need To Diminish Depression Depression is the problem of the day. Many people suffer from this problem and are really suffering. The [...]

ADD YOUR LINK HERE

Resources:

Alternative Health

Anxiety

Depression

Health

Mental Health

Nutrition

Psychotherapy

Self Help